[1] Chinese Society of Respiratory Medicine, Asthma Group. Chinese expert consensus on the use of Omalizumab in allergic asthma (2021 Version)[J]. Chinese Journal of Tuberculosis and Respiratory Diseases(中华结核和呼吸杂志), 2022, 45(4): 341-354. [2] LI JY, LIU Y, LUO L, et al.Clinical efficacy and safety of omalizumab in treatment of moderate and severe allergic asthma[J]. China Medicine(中国医药), 2022, 17(11): 1638-1642. [3] LIMB SL, STARKE PR, LEE CE, et al.Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma[J].The Journal of Allergy and Clinical Immunology, 2007, 120(6): 1378-1381. [4] KALTEREN WS, SCHREURS MWJ, JORRITSMA-SMIT A, et al.Ocular myasthenic syndrome, adverse reaction to omalizumab? A case report[J]. British Journal of Clinical Pharmacology, 2017, 83(10): 2330-2332. [5] LIU JJ, WANG YL, WANG D, et al.Analysis of one case of delayed anaphylaxis induced by clarithromycin tablets[J].Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(12): 946-948. [6] GUAN JL, LIU HP, JI B.A case study of delayed anaphylaxis induced by iodohexol[J]. Pharmaceutical Care and Research(药学服务与研究), 2020, 20(5): 396-399. [7] LIU M, WANG HX.Overview of causality evaluation methods for adverse reactions in drug clinical trials and consideration of existing problems[J]. The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2023, 39(8): 1206-1211. [8] DAI RR, ZHOU X.Progress and application of Omalizumab in the treatment of asthma[J]. International Journal of Respiration(国际呼吸杂志), 2016, 36(13): 998-1001. [9] GON Y, MARUOKA S, MIZUMURA K.Omalizumab and IgE in the control of severe allergic asthma[J]. Frontiers in pharmacology, 2022, 13: 839011. [10] CHEN XQ, JIA XY, WU JJ, et al.Efficacy and safety of omalizumab in patients with the refractory allergic asthma:a meta-analysis[J]. National Medical Journal of China(中华医学杂志), 2022, 102(28): 2201-2209. [11] HUMBERT M, BOUSQUET J, BACHERT C, et al.IgE-mediated multimorbidities in allergic asthma and the potential for omalizumab therapy[J]. The Journal of Allergy and Clinical Immunology in Practice, 2019, 7(5): 1418-1429. [12] FU Z, XU YS, CAI CQ.Efficacy and safety of omalizumab in children with moderate-to-severe asthma: a meta-analysis[J]. The Journal of Asthma, 2021, 58(10): 1350-1358. [13] ZHANG HP, SUN YY, TIAN DL.Literature analysis of adverse drug reactions of omalizumab[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2022, 42(18): 1939-1942. [14] WU PH, DONG C, XIE JX, et al.Preliminary clinical observation of Omalizumab therapy for moderate to severe asthma[J]. Chinese Journal of Tuberculosis and Respiratory Diseases(中华结核和呼吸杂志), 2021, 44(7): 611-618. [15] LAURA D, ALVISE S, FRANCESCA M, et al.A severe adverse reaction to omalizumab therapy in chronic spontaneous urticaria[J].Dermatologic Therapy, 2020, 33(1): e13204-e13204. [16] JEAN-LOUIS M, AGNS S, ISABELLE L, et al.Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods[J]. Joint Bone Spine, 2006, 73(6): 629-632. [17] LI HL, LI N, ZHENG XL.112 cases of hypersensitivity induced by methylprednisolone sodium succinate[J].Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(2): 155-159. [18] BIAN S, ZHANG P, LI L, et al.Anaphylaxis associated with allergen specific immunotherapy, omalizumab, and dupilumab: a real world study based on the US Food and Drug Administration Adverse Event Reporting System[J]. Frontiers in Pharmacology, 2021, 12: 767999. [19] GAN H, WANG L, FU W, et al.Rapid subcutaneous desensitization for the management of delayed hypersensitivity reactions to omalizumab: a case report[J]. Journal of Clinical Pharmacy and Therapeutics, 2019, 44(3): 486-488. |